digoxin vs enzalutamide
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of digoxin and enzalutamide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.3 Laboratory Test Interference XTANDI can interfere with certain digoxin immunoassays (e.g., Chemiluminescent Microparticle Immunoassays), resulting in falsely elevated digoxin plasma concentration results. Notify the laboratory conducting the digoxin plasma concentration assay to use an appropriate method in patients receiving XTANDI and digoxin [see Warnings and Precautions ( 5.8 )] .
Lanoxin
Xtandi
Digoxin (Lanoxin) is a medicine that helps your heart pump better. It is used to treat heart failure and control irregular heartbeats.
Xtandi contains enzalutamide. It is used to treat prostate cancer that is resistant to certain treatments.
Digoxin is used to treat mild to moderate heart failure in adults. It helps the heart pump more blood with each beat. Digoxin is also used in children with heart failure to help their heart work better. In adults, it can control a fast and irregular heartbeat called atrial fibrillation.
Xtandi is used to treat prostate cancer in men. It is for prostate cancer that keeps growing even when treated with hormone therapy or after surgery. Xtandi can treat prostate cancer that has spread or has not spread.
Digoxin belongs to a class of drugs called cardiac glycosides. It works by making the heart muscle contract more strongly. It also slows down the electrical signals in the heart, which can help control irregular heartbeats.
Xtandi blocks the effect of hormones called androgens, like testosterone. Androgens can help prostate cancer cells grow. By blocking androgens, Xtandi can slow or stop the growth of prostate cancer.
- • Nausea
- • Vomiting
- • Diarrhea
- • Dizziness
- • Headache
- • Muscle or joint pain
- • Feeling tired
- • Hot flashes
- • Constipation
- • Less hungry
- Dyspnoea 6,065
- Nausea 4,754
- Dizziness 4,439
- Fatigue 4,175
- Atrial Fibrillation 3,974
- Fatigue 10,159
- Death 7,667
- Malignant Neoplasm Progression 5,409
- Prostatic Specific Antigen Increased 4,295
- Asthenia 4,120
Digoxin can cause serious side effects, including dangerous heart rhythms. You are at higher risk if you have certain heart conditions or kidney problems. Tell your doctor right away if you have nausea, vomiting, vision changes, or an irregular heartbeat.
Xtandi can cause seizures. If you have a seizure while taking Xtandi, stop taking it permanently. Xtandi can also cause a condition called posterior reversible encephalopathy syndrome (PRES). If you experience PRES, stop taking Xtandi. Xtandi can harm an unborn baby, so men with partners who can get pregnant should use effective birth control during treatment and for 3 months after the last dose.
It is not known if digoxin can harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. The medicine passes into breast milk, but it is unlikely to harm the baby.
Xtandi is not for use in women. It can cause harm to an unborn baby if taken by a pregnant woman. Men who are taking Xtandi and have partners who can get pregnant should use effective birth control during treatment and for 3 months after the last dose.
How to Read This digoxin vs enzalutamide Comparison
digoxin is classified in the Cardiac Glycoside drug class, while enzalutamide sits within the Androgen Receptor Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, digoxin has 23,407 submissions while enzalutamide has 31,650. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to enzalutamide interferes with the way labs measure digoxin in your blood, leading to test results that look higher than they really are. this is a problem with the test itself, not the actual amount of drug in your body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for digoxin or enzalutamide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.